Epigenetic therapies to differentiate and eradicate leukaemia stem cells [ 2019 - ]

Research Grant

Researchers: Dr Omer Gilan (Principal investigator)

Brief description Leukemia stem cells (LSC) are often resistant to conventional and targeted therapies and therefore serve as the seed for leukaemia relapse. The overall aim of this project is to use small molecule therapies to block the activity of a particular protein (LSD1) in LSC in order to differentiate them and expose a vulnerability to another epigenetic therapy called a BET inhibitor. Together, these epigenetic therapies will differentiate and eradicate LSC, leading to improved outcome in AML.

Funding Amount $665,005.00

Funding Scheme Project Grants

Notes New Investigator Grant